The vast majority of human genes contain more than one exon; therefore, the intervening introns need to be spliced from the nascent transcript and the exons joined to form an mRNA that can be translated into a protein.
. Genes producing long non-coding RNAs (lncRNAs) also typically contain several exons and often display evidence for alternative splicing using similar mechanisms to those used for protein-coding mRNAs 3 . The mechanisms of splicing regulation and its perturbation in disease have been reviewed elsewhere 4, 5 . Here, our emphasis is on non-canonical splicing, which includes cryptic splice sites that are located far from the currently annotated exons and unconventional mechanisms that deviate from the well-defined rules of splicing. New methods to sequence the transcriptome, together with dedicated analysis pipelines
, have revealed a broad prevalence of non-canonical splicing events that can generate cryptic exons [6] [7] [8] [9] [10] , microexons [11] [12] [13] , recursive splicing 14, 15 , circular RNAs (circRNAs) [16] [17] [18] [19] [20] , retained introns 21-25 and exonic introns (exitrons) 25, 26 , among others. In this Review, we discuss known splicing mechanisms and functions, as well as the evolutionary potential of these events. We describe how mutations can cause disease by disrupting transcriptome integrity through non-canonical splicing, and how the cellular quality control systems defend the transcriptome from such perturbations. Finally, we explain how unconventional splicing mechanisms can be targeted or exploited for new therapeutic strategies.
Types of non-canonical splicing
Splicing fidelity is achieved by the combinatorial recognition of specific sequences within precursor mRNA at many steps during the splicing process 4, 27 . The first, and possibly most important, aspect of combinatorial recog nition is described by the exon definition mechanism, which was proposed to explain how exons are recognized as functional units in metazoan organisms that contain long introns 27, 28 . This process involves interactions between factors bound to the flanking splice sites (the U1 and U2 small nuclear ribonucleoproteins (snRNPs) and the U2 auxiliary factor complex (U2AF complex)) and serine/arginine-rich proteins (SR proteins) bound to the exonic enhancer sequences. First, we discuss cryptic exons, microexons and recursive splice sites (RS sites), which often require unconventional exon definition mechanisms. Next, we discuss non-canonical splicing mechanisms that result from either lower or higher spli cing efficiency than normal (such as retained introns and exitrons), changes in the usual order of splicing (such as circRNAs and chimeric RNAs) or changes in the consensus sequence (such as atypical splice sites).
Cryptic splice sites and exons. Introns of ENSEMBLannotated genes constitute ~23% of the human genome; within such a vast sequence space it is inevitable that many sequences similar to the consensus motifs of canonical splice sites are present by chance. Such sequences are known as cryptic splice sites. To prevent uncontrolled splicing at cryptic sites, an exon definition mechanism has evolved to maintain splicing fidelity, which explains why most individual cryptic splice sites do not efficiently initiate splicing 27, 28 . Nevertheless, over half a million non-annotated splicing events have been
Splice sites
Sequences at the boundary of exons and introns, which contain motifs that recruit small nuclear ribonucleoproteins and RNA-binding proteins to initiate the splicing reaction. 3′ and 5′ splice sites are located upstream and downstream of exons, respectively.
Cryptic exons
Exons that are not annotated by current genomic databases, such as ENSEMBL, and are often only revealed after removing a repressive RNA-binding protein or after a genomic mutation that increases their splicing efficiency.
Lessons from non-canonical splicing
Christopher R. Sibley 1, 2 *, Lorea Blazquez 1 discovered through the analysis of mouse and human RNA sequencing (RNA-seq) data 11, 14, [29] [30] [31] . Even though many of these events may be splicing 'mistakes' that are tolerated by the cell and have no function, targeted genome-editing experiments are beginning to uncover the functions of specific cryptic splice sites 31 . Moreover, cryptic splice sites can be present in a manner that can define non-annotated, or cryptic, exons 32 . These exons often introduce premature termination codons (PTCs) into the resulting transcripts, which can target them for nonsense-mediated decay (NMD) in the cytoplasm [33] [34] [35] ( FIG. 1a) . In some cases, abnormal splicing also leads to transcription-coupled surveillance mechanisms that can decrease the expression of resulting transcripts 36 . These quality control pathways often decrease the expression of transcripts containing cryptic exons, which makes these exons more difficult to detect and annotate during transcriptome sequencing analysis [6] [7] [8] [9] [10] . Cryptic exons often emerge from transposable elements (TEs). In primates, antisense Alu sequences are the best substrates for the exonization process, as they require a low number of mutations to form potent splice sites 37 . The evolution of the Alu family consisted of two phases. The original Alu monomers first arose from a fusion of the 5′ and 3′ ends of the 7SL gene, which encodes an RNA component of the signal recognition particle (SRP); then an additional fusion of these monomers led to the modern Alu elements that are composed of left and right arms joined by an adenosine-rich linker (A-linker) and followed by a poly(A) tail (FIG. 1b) 38 . Notably, more than 330,000 Alu elements (annotated by RepeatMasker) are present in introns of protein-coding genes in an antisense orientation, where they are transcribed in a reverse orientation, thus containing two poly(U) tracts (U tracts) instead of the poly(A) tail and A-linker. These U tracts can function as binding sites for splicing factors, especi ally U2AF2 and T cell-restricted intracellular antigen (TIA) proteins, which can induce the formation of cryptic or alternative Alu exons 8, 37, 39 . Mechanisms regulating the splicing of Alu exons and other cryptic exons have been uncovered in s tudies that map the binding sites of RNA-binding proteins (RBPs) using crosslinking and immunoprecipitation (CLIP), individual-nucleotide-resolution CLIP (iCLIP) and other related techniques 40 . The Alu-derived exons were found to be tightly repressed by heterogeneous nuclear ribo nucleo protein C (HNRNPC), which can displace U2AF2 from the long U tracts 8 (FIG. 1b) , and other cryptic exons were found to be repressed by NOVA RBPs 7 , RBP fox-1 homologue 2 (RBFOX2) 6 and transactivation response element DNA-binding protein 43 (TDP43) 9 . Together with deep sequencing of RNA from tissues, these studies revealed thousands of previously unknown cryptic exons, and some of these are becoming recognized as regulated alternative exons 10 (FIG. 1a) . Interestingly, repressive sequences were found to be more common at cryptic exons compared to the established alternative exons that emerged from TEs, indicating that a loss of repression may have a role in the formation of new exons 41 .
Microexons.
Exons that are shorter than 30 nt have traditionally been referred to as microexons [42] [43] [44] . New computational methods for the analysis of sequencing data have revealed hundreds of previously unidentified microexons, 60% of which are preferentially included in neuronal tissues [11] [12] [13] 44 . Interestingly, microexons tend to be flanked by intronic motifs that are required for their inclusion and which bind to RBPs, such as serine/ arginine repetitive matrix 4 (SRRM4; also known as nSR100) 12 , RBFOX or polypyrimidine tract-binding protein 1 (PTBP1) 13 . SRRM4 is an SR-related protein that acts in an unusual way. Unlike other SR proteins that bind to exonic enhancers, SRRM4 binds to enhancers that are embedded within the unusually long
Box 1 | Identification of non-canonical splicing events
High-throughput methodologies, and in particular RNA sequencing (RNA-seq), have created opportunities for transcriptome-wide annotation of rare, cell-type-specific transcripts and non-canonical splicing events in our transcriptomes 12, 14, 15 . cDNA generated from poly(A)-purified RNA in mRNA-seq primarily detects fully spliced mRNAs that have passed the cellular quality control mechanisms, whereas cDNA generated with random primers in total RNA-seq also identifies the intermediate steps of splicing reactions 14, 15, 48, 185 . To study non-canonical splicing, several alignment algorithms have been tailored for the discovery of novel splice junctions using RNA-seq data 11, 29, 30 . A particularly great diversity of transcripts was found in the brain, in agreement with the great variety of cell types and functions that exist in this organ 10, 14, 29, 30 . Even though many of these transcripts are rare and non-functional, some are functionally important non-canonical splicing events. One way to distinguish those that may have a function is to focus on novel junctions that contact conserved sequences that bear features of splicing elements, such as proximally spaced 3′ and 5′ splice sites (that is, within typical exon size limits), branch points, exonic enhancers and other regulatory elements 10, 14, 26, 31 . More specialized methods for preparing and analysing RNA-seq data have led to the discovery of new types of exons and RNAs. For example, several commonly used alignment algorithms require a minimum length of the seed sequence for the alignment, which generally limits the detection of exons to those longer than 30 nt, thereby excluding microexons. To overcome this limitation, alignment algorithms were modified to use shorter seeds and to allow longer reads to be mapped in multiple parts 11 . If segments of a long read are mapped to two exons in a way that leaves an unmapped intervening sequence, this sequence can then be mapped back to the intronic sequence present between the two exons, with priority given to conserved sites flanked by proximally spaced 3′ and 5′ splice sites consistent with a <30 nt microexon 11,13,44 (FIG. 1c) . Alternatively, custom alignment files incorporating all putative cryptic exons with flanking splice sites can be used for mapping 12 . Information on splicing efficiency can also be gained through analysis of intronic reads. For example, intron retention can be examined by the ratio of exon-intron junction reads relative to junction spanning reads, or by comparing read coverage across the intron to the flanking exons 21, 23, 24 . Moreover, co-transcriptional splicing patterns can be visualized across introns in total RNA-seq data as 'saw-tooth' patterns 14, 15, 31, 48 . Specifically, the RNA abundance at the start of a long intron is higher than at the end owing to the presence of nascent transcripts in various stages of transcription and because splicing cannot proceed until the 3′ splice site is transcribed 47, 48 . Novel junctions that overlap clear troughs in the co-transcriptional splicing patterns often identify recursive splice sites (RS sites) 14, 15 (FIG. 2a) .
Dedicated computational approaches also facilitated the discovery of circular RNAs (circRNAs) and chimeric transcripts 66, 67, 186, 187 . In the simplest method for the discovery of circRNAs, unaligned reads are split into two parts before being re-mapped to exons. If the second part maps to an exon upstream of the first part, these are then considered as circRNA candidates 17 (FIG. 4b) . This local re-ordering of the alignments distinguishes circRNAs from chimeric transcripts, which can also be identified by discordant alignments 188, 189 (FIG. 4c-d) . Experimentally enriching the sample preparation for non-linear RNAs (using the RNase R exoribonuclease) before cDNA library preparation can further enhance circRNA discovery 65, 67 .
Exonic introns
(Exitrons). Introns located within annotated exons.
polypyrimidine tract present upstream of microexons, thereby compensating for the limited space available for enhancer sequences within the microexons (FIG. 1c) .
Recursive splice sites. RS sites, also referred to as 'zerolength exons' , are defined by a sequence that combines the 3′ and 5′ splice site consensus motifs. This allows an intron to be spliced in several consecutive steps: the 3′ splice site is used to splice the preceding part of the intron, which reconstitutes a full 5′ splice site that is then used to splice the remaining part of the intron (FIG. 2) . First discovered in the long introns of 3 Drosophila melanogaster genes 45, 46 , analyses using total RNA-seq and iCLIP identified 197 RS sites in D. melanogaster 15 and 11 in humans 14, 15 . In addition to the detection of splice-junction reads bearing the RS site motif, these studies also required the presence of co-transcriptional splicing patterns (FIG. 2a) , which can only be reliably evaluated in long introns with high read coverage 14,47,48
. Accordingly, these numbers are probably underestimated. For instance, 419 cryptic splicing events were found at putative RS junctions in human samples prior to considering the co-transcriptional splicing patterns 14 . Nature Reviews | Genetics contain proximally spaced sequences that resemble splice sites (such as GU for 5′ splice sites and YAG for 3′ splice sites), which can in some cases lead to splicing of 'cryptic' exons. Cryptic exons often introduce premature termination codons, which may target the resulting transcripts for nonsense-mediated decay (NMD). Such NMD exons are common within transcripts that encode splicing activators and function as part of autoregulatory mechanisms [33] [34] [35] . In this example, a serine/arginine-rich (SR) protein enhances the inclusion of an NMD exon within its own mRNA as part of a negative autoregulatory feedback that maintains appropriate steady-state abundance. b | An Alu element is normally composed of two arms, which contain an adenine-rich linker (A-linker; left arm) and a poly(A) tail (right arm). The Alu element can become retrotransposed into the antisense strand relative to the gene, so that transcription of the gene produces an antisense Alu sequence that contains two poly(U) tracts (U tracts) at the beginning of each arm. Many such antisense Alu elements are capable of forming cryptic exons owing to the presence of splice-site-like motifs 37 . However, they are normally repressed by a heterogeneous nuclear ribonucleoprotein C (HNRNPC) tetramer (C, green circle), possibly because each U tract can bind the two RNA recognition motif domains that are present on the opposite surfaces of the tetramer (as indicated by the double arrow) 8, 190 . The example provided here shows the U tracts around the Alu exon from the CD55 gene (encoding CD55 molecule). Mutations in the U tracts can decrease the binding of HNRNPC, allowing the binding of U2 small nuclear RNA auxiliary factor (U2AF2) and T cell-restricted intracellular antigen 1 (TIA1), which initiate splicing of a cryptic Alu exon 8, 37, 39 . c | Microexons (denoted here by μ) can be detected from gapped regions in sequencing reads 11, 13, 44 . After mapping of multiple parts of the sequence read to flanking exons, unmapped intervening sequences are aligned to the intronic sequence present between the two exons, with preference given to those that are flanked by conserved splice site motifs. Inclusion of microexons can be enhanced by RNA-binding proteins (RBPs), such as serine/ arginine repetitive matrix 4 (SRRM4), an SR protein that binds upstream of microexons and promotes microexon splicing. Inclusion of microexons typically leads to the modulation of overlapping or adjacent protein domains and a change in protein activity. SRRM4 is reduced in patients with autism spectrum disorder (ASD), leading to decreased inclusion of microexons 12 .
Exon definition mechanism
The process by which exons are recognized and defined as functional units through interactions between multiple small nuclear ribonucleoproteins (snRNPs) and RNA-binding proteins (RBPs), especially U1 and U2 snRNPs and serine/arginine-rich proteins.
Small nuclear ribonucleoproteins
(snRNPs). Ribonucleoprotein complexes assembled around the small nuclear RNAs that interact with splice sites or the branch point on pre-mRNA and thereby coordinate and catalyse the splicing reaction. 
U2 auxiliary factor complex

Recursive splice sites
(RS sites). The sites of recursive splicing, which consists of a 3′ splice site that is followed by a sequence that reconstitutes a 5′ splice site after the first splicing event.
Seed sequence
The section of a sequencing read that is used to align the read to the genome or transcriptome Nonsense-mediated decay (NMD). A pathway that initiates decay of certain transcripts, especially those containing a premature termination codon.
Alu elements
Retrotransposons, ~300 nt long, belonging to the family of short interspersed elements (SINEs), which originally derived from 7SL signal recognition particle RNA.
Notably, intrasplicing is another mechanism that can affect alternative splicing by using non-annotated splice sites. However, in this instance, the first splicing reaction reconstitutes a new 3′ splice site, which can then be used by an upstream exon to remove the remaining intron 49 .
Even though RS sites do not normally lead to exon splicing, they do employ the exon definition mech anism in vertebrates (FIG. 2b) . These RS sites are present at the start of cryptic exons, referred to as RS site exons 14 . Both the RS sites and the downstream 5′ splice site that Nature Reviews | Genetics . The 'saw-tooth' patterns that overlap novel junction reads indicate splicing at deep intronic loci and are candidates for recursive splicing 14, 15 . Here, the upstream exon first uses a 3′ splice site (3ss) to remove the first part of the intron. This process reconstitutes a 5′ splice site (5ss) that can then be used to remove the next section of the intron. This special type of splice site is referred to as a recursive splice site (RS site). b | Recursive splicing in vertebrates requires the RS site to overlap a cryptic 'RS exon', which initiates the exon definition mechanism that is required for the recognition of the 3′ splice site (YAG) of the RS site 14 . After the first splicing step, the 5′ splice site (GURAG) of the RS site competes with the 5′ splice site of the RS exon. In the second step, the outcome of this competition determines whether the RS exon is skipped, owing to recursive splicing, or included as a nonsense-mediated decay (NMD) exon. Whereas the preceding exons from major isoforms end in sequences that favour RS exon skipping, the minor isoforms and cryptic elements end in sequences that favour RS exon inclusion.
Crosslinking and immunoprecipitation
(CLIP). A method used to identify the RNA targets bound by an RNA-binding protein of-interest that employs crosslinking, immunoprecipitation and stringent purification of protein-RNA complexes by SDS-PAGE.
NOVA RBPs
A joint name for RNA-binding proteins encoded by two partially redundant genes that are expressed in the brain, neuro-oncological ventral antigen 1 (NOVA1) and NOVA2.
NMD exons
(Nonsense-mediated decay exons). Exons that contain a premature termination codon and are therefore targeted for NMD.
is required for exon definition are highly conserved. Definition of the RS exon is essential to initiate splicing at the 3′ splice site. After splicing of the preceding intron, the RS site reconstitutes a strong 5′ splice site, which leads to skipping of the RS exon through recursive splicing. Whereas the exon definition mechanism is required for recursive splicing in humans and zebrafish, it remains unclear how RS sites are defined in the fruitfly. The first RS sites discovered in the fruitfly overlapped with the start of annotated exons, indicating that an exon definition mechanism might be involved 45, 46 . Conversely, the 3′ splice site of intronic RS sites is often strongly conserved across Drosophila, which is consistent with the sensitivity of fruitfly recursive splicing to the depletion of U2AF2 (REF. 15 (FIG. 3a) . Most often, it is caused by an inefficient recognition of canonical splice sites 53 . Under conditions of limited spliceosome availability, such as downregulation of spliceosomal components, deficient splice site recognition can affect hundreds of introns in this way 24 . Moreover, the inclusion of shorter introns in mammalian cells can be more dependent on intron definition, a mechanism that brings the splice sites at both ends of the intron into closer proximity 27 . This mechanism can be regulated by RBPs that bind at both ends of the intron and interact with each other 54 . These proposed mechanisms concur with the findings of generally weaker 5′ and 3′ splice sites and the shorter length of the retained introns compared to other introns 21, 53, 55 . Moreover, retained introns have a higher GC content compared to average introns, which might make them more sensitive to RNA polymerase II stalling 21, 53 . Certain RBPs can also promote specific intron retention events 22, 56, 57 . For example, PTBP1 can repress the recognition of a canonical splice site in an intron of the FOSB gene 56 , whereas polyadenylate-binding protein 2 (PABP2; also known as PABPN1) promotes retention of the last intron within its own transcript by binding to an A-rich region in the 3′ UTR 57 . Finally, depletion of the exon junction complex components also leads to retention of long introns in D. melanogaster 58, 59 , although apparently not in human cells 60 .
Exitrons. Some alternatively spliced introns are also present within regions annotated as exons. These introns are rarely spliced and are therefore referred to as exitrons or cryptic introns 25, 26 (FIG. 3b) . A total of 923 exitrons have been discovered within regions that are normally annotated as exons 26 . Similar to retained introns, exitrons are shorter than average introns and have weak splice sites, which can explain why they are retained under normal conditions. Exitrons are formed from some of the longest known exons in humans and have a higher GC content than typical exons. They are formed when cryptic splice sites within an exon pair with canonical splice sites that flank the same exon, thereby leading to the definition of two smaller exons 26 . Unlike retained introns, exitrons normally do not contain PTCs. Instead, their removal can change protein structure or lead to frameshifts that introduce PTCs, which can target the resulting transcripts for NMD (FIG. 3b) . Circular RNAs. CircRNAs are formed as a result of pre-mRNA splicing that does not follow the canonical 5′ to 3′ order 20, 61 . The mechanism responsible for this is referred to as back splicing, or head-to-tail splicing, in which a branch point upstream of an exon attacks a downstream splice donor [62] [63] [64] . In some cases this happens with a single exon, whereas in others the start of an upstream exon splices to the end of a downstream exon, producing multi-exonic circRNAs 17 (FIG. 4a) . In these multi-exonic circRNAs, the intervening intron can be spliced out. We refer to such single-or multi-exonic Nature Reviews | Genetics . Intron retention events are characterized by numerous features including weak splice sites, high GC content and short intron lengths. Trans-acting factors such as RNA-binding proteins (RBPs), the spliceosome and the exon junction complex (EJC) can also regulate specific intron retention events. The resulting transcripts are typically either retained in the nucleus or targeted for nonsense-mediated decay (NMD) in the cytoplasm or may result in truncated proteins 21, 53, 55 . b | Exonic introns (exitrons) are introns within annotated protein-coding exons that can be removed owing to the presence of internal splice site motifs within the exon 25, 26 . Exitron-containing exons are longer than typical exons, and removal of the exitron can lead to changes in protein structure or degradation through NMD.
circular transcripts that lack introns as 'exonic circRNAs' . Alternatively, if the intron between the exons is retained, the resulting circular transcript is referred to as 'exon-intron circRNA' (REF. 20) (FIG. 4a) . Finally, 'intronic circRNAs' can be produced from intron lariats that are resistant to de-branching owing to the presence of C-rich motifs near the branch point 20 . These diverse types of circRNAs have been discovered in all domains of life [16] [17] [18] [19] [20] 65, 66 . Although most are rare, some are highly abundant in a specific tissue owing to their resistance to Nature Reviews | Genetics
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Linear transcript CircRNA b Identification of circRNAs using RNA-seq a Figure 4 | Formation of circularRNAs and chimeric transcripts. a | Circular RNAs (circRNAs) are produced by head-to-tail splicing and can be either mono-or multi-exonic. In this multi-exonic example, the 3′ splice site of an upstream exon becomes spliced to the 5′ splice site of a downstream exon to generate a circular transcript in which the intervening intron is either removed (exonic circRNA) or retained between the two circularized exons (exon-intron circRNA) 20 . circRNA formation is promoted when the pre-mRNA regions flanking the exon termini are brought into close proximity. This can be due to the action of RNA-binding proteins (RBPs) such as quaking (QKI) or muscleblind-like (MBNL), which bind to the flanking regions 74, 75 . Alternatively, this can be due to RNA hybridization of the flanking regions, which can be caused by Alu elements in primates 70 . b | CircRNAs are resistant to RNase R exoribonuclease activity, which can be used for their enrichment during preparation of cDNA libraries. They can then be detected in RNA sequencing (RNA-seq) data by junction reads that are in a head-to-tail orientation [16] [17] [18] [19] . c | Chimeric RNA products can also be produced by cis-splicing when transcript termination is deficient 76 . This process results in read-through of one gene into its neighbouring gene, before splicing occurs between the penultimate exon of gene 1 and the second exon of gene 2, which is seen in the chimeric cathepsin C (CTSC)-RAB38 gene in some cancers. d | Trans-splicing occurs when exons of two different transcripts become spliced together [80] [81] [82] [83] [84] [85] [86] [87] . Alternatively, the same chimeric transcripts can be produced when genes become fused, such as in JAZF1-SUZ12 gene fusion in some cancers, which leads to the same chimeric transcript being produced by a linear splicing reaction.
Intrasplicing
An unconventional splicing mechanism in which splicing to a 3′ splice site reconstitutes a new 3′ splice to be used in a subsequent splicing step.
RS site exons
(Recursive splice site exons). Exons that follow an RS site and which are required for the exon definition mechanism that initiates splicing at the RS site.
Spliceosome
A macromolecular machine consisting of small nuclear ribonucleoproteins (snRNPs) and additional RNA-binding proteins (RBPs) that coordinate and catalyse the splicing reaction.
Chimeric transcripts
Transcripts that are formed when sections of two or more different genes are joined together in a new transcript either by splicing or as a result of chromosomal fusions.
Axonogenesis
The generation and outgrowth of axons during neuronal development.
exonucleases 67 (FIG. 4b) . Many have tissue-specific expression patterns 16, 17, 20, 66 , and in the central nervous system they tend to be enriched within neuronal dendrites 68 . Head-to-tail splicing can be promoted by the presence of intronic inverted repeat sequences, which hybridize and thereby bring the ends of the relevant exons into close proximity [69] [70] [71] [72] (FIG. 4a) . In primates, hybridization can be directed by inverted Alu repeats in flanking introns 70 . As inverted Alu repeats are known to be a target for RNA editing, it is thus possible that the formation of circRNAs could be regulated by editing. Indeed, dsRNA hybridization sites that are edited by adenosine deami nase acting on RNA (ADAR) are seen in introns that flank circRNAs in Caenorhabditis elegans 73 . However, the formation of a dsRNA structure is not always required for circRNA formation 69 . RBPs, such as quaking (QKI) and muscleblind-like (MBNL) proteins are also able to regulate circ RNA biogenesis through binding sites in the flanking introns Chimeric RNAs. Modified algorithms for the analysis of RNA-seq data can identify chimeric RNAs, which are produced when splicing joins the exons of different genes
. Cis splicing was proposed to result from deficient transcriptional termination, which allows proxi mal genes to be transcribed as a single unit, thereby resulting in splicing of the penultimate exon of the upstream gene to the second exon of the downstream gene 76 . Such chimeric transcripts that combine exons of adjacent genes have been detected in several human tissues [77] [78] [79] (FIG. 4c) .
By contrast, trans-splicing joins exons derived from distant genomic locations (FIG. 4d) . The resulting chimeric transcripts have been best documented in trypanosomes, C. elegans and insects [80] [81] [82] [83] [84] [85] and, to a lesser extent, in humans 86, 87 . Atypical splice sites. More than 99% of human introns are spliced by the major U2-dependent spliceosome. Most typical 5′ splice sites start with GTRAG, whereas the remaining ones, which retain the starting GT, have a stronger preference for AG at the 3′ end of the preceding exon; the 3′ splice sites end with CAG, TAG or more rarely, AAG (FIG. 5a) . The introns spliced by the minor U12-dependent spliceosome can be distinguished by the longer consensus sequence at the 5′ splice site and at the branch point 88, 89 (FIG. 5b) . In contrast, 5′ splice sites that start with a GC are the most common atypical U2-type splice sites 90, 91 (FIG. 5c) . In each case, the 3′ splice site is normally preceded by a branch point that contains an adenine nucleotide. It is common that multiple branch points are present 92 , and this can affect the choice of alternative 3′ splice sites. This was recently demonstrated genome-wide following mutation of splicing factor 3b subunit 1 (SF3B1) [93] [94] [95] . Several mechanisms could explain the recognition of these atypical splice sites, including shifted base pairing of small nuclear RNAs (snRNAs) 96 and bulged nucleotides that retain base pairing to snRNAs 97 . Some sites were also found to be modified by A-to-I RNA editing, in which inosine is effectively read as a guanosine 91, 98 .
An example of this mechanism is the ADAR2-dependent editing of an AA-3′ dinucleotide within its own premRNA, which then functions as a strong AG-3′ splice site to change the splicing of its transcript as part of an autoregulatory mechanism 98 . Finally, the unconventional cytoplasmic splicing of X-box-binding protein 1 (XBP1) and other mRNAs during the unfolded protein response, which employs the RNase inositolrequiring enzyme 1 (IRE1; also known as ERN1) and the tRNA-splicing ligase RtcB homologue (RTCB), can create new exon-exon junctions that lack the standard consensus sequences [99] [100] [101] .
The functions of non-canonical splicing Non-canonical splicing events contribute to a great diversity of cellular mechanisms and biological functions. Perhaps the best understood of these functions is that of microexons, which are enriched in genes associated with synapse biology and axonogenesis 12 . Microexons are highly conserved, and their length generally comes in multiples of three, thereby preserving the open reading frame (ORF) [11] [12] [13] . Microexons are enriched within modu lar interaction domains, where they tend to encode charged residues that are accessible at the surface, and often overlap lipid-or peptidebinding domains 12,13,102 (FIG. 1c) . It has been shown that the inclusion of micro exons alters the interactomes of several proteins 12 . Owing to their common brainspecific splicing patterns, microexons have a major role in increasing proteome diversity within the brain. Therefore, it is not surprising that widespread skipping of microexons following the loss of SRRM4 in mice leads to neurodevelopmental defects 103 . Another type of newly discovered event that leads to new protein variants are exitrons, most of which preserve the reading frame and are enriched within disordered regions of the encoded proteins 26, 104 (FIG. 3b) .
Other forms of non-canonical splicing most often have a role in regulating gene expression. One of the best studied examples is the neuronally expressed circ-RNA cerebellar degeneration-related protein 1 antisense RNA (CDR1-AS; also known as ciRS-7), which contains at least 63 conserved microRNA (miRNA) miR-7 binding sites that sequester this miRNA, subsequently increasing translation of its mRNA targets 16, 17 . Moreover, circ RNAs can contribute to the mechanisms that regulate transcription or splicing 20 . For example, by enhancing the production of circRNAs in its own transcript, the MBNL1 RBP decreases the number of translation-competent transcripts produced from its own gene 74 . In fact, many splicing factors regulate the splicing of cryptic exons, introns or circRNAs in their own transcripts or those of other RBPs as part of auto-or cross-regulatory mechanisms 6 ,7,20,21,24,33-35,55,105 (FIG. 1a) . Retained introns often lead to the retention of the host mRNA in the nucleus where it undergoes exosome-mediated degradation 22 . If exported to the cytoplasm, most retained introns introduce PTCs and may thereby promote NMD of the resulting transcript or lead to the production of truncated proteins 22,23,106,107 (FIG. 3a) . Intron retention was found to coordinate the expression of related genes in granulocyte differentiation 24 at certain stages of the cell cycle 55 and across tissues 21 . Interestingly, intron retention is more common in transcripts that are less required for the physiology of a particular tissue 21 . The function of recursive splicing in regulating gene expression remains to be fully understood. In humans, RS sites are found in the extremely long introns of genes that are expressed mainly in the brain and function in neuronal axon guidance and cell adhesion 14, 15 . It is tempting to speculate that recursive splicing could be important for the splicing integrity of these introns. However, steric blocking of recursive splicing failed to reduce the overall splicing of the long intron in two human genes 14 . An alternative regulatory role was proposed for human RS sites 14 . These RS sites are Nature Reviews | Genetics followed by RS exons, which are spliced out of dominant isoforms but are included in minor isoforms that arise from the use of upstream cryptic exons or rare alternative promoters (FIG. 2b) . The reason for the inclusion of RS exons in minor isoforms is that the preceding cryptic exons end with suboptimal sequences, and therefore they do not reconstitute a sufficiently strong 5′ splice site at the RS site. Interestingly, most RS exons contain PTCs, and therefore their inclusion prevents translation of full-length proteins and targets the resulting transcripts to NMD (FIG. 2b) . It remains to be seen how many RS sites are involved in the regulation of alternative splicing.
Evolutionary perspectives
Even though exemplary functions of individual noncanonical splicing events have been discussed in this Review, the same function cannot be ascribed to all events of the same type. For example, even though a few circRNAs can sequester a miRNA, most of them are not abundant enough to have such a function 108 . It is likely that many transcripts produced by non-canonical splicing have no function, and their presence reflects the capacity of cellular quality control mechanisms to protect from potential damaging effects of these transcripts. Most newly emerging exons contain PTCs, and their initial emergence probably produces truncated or misfolded proteins that may be deleterious for the organism. It is therefore not surprising that quality control mechanisms minimize the deleterious effects of such events. These include RBPs or snRNP complexes that have secondary activities aside from their usual roles in spliceosome function or the regulation of canonical exon splicing. These RBPs or snRNPs can repress splicing of cryptic exons 8, 74, 75, 109, 110 , edit the nascent RNA to repress splicing 111, 112 , prevent mRNA export, or decrease the stability of aberrant mRNAs 8, 60, 107, 113, 114 .
Many non-canonical splicing events are introduced by transposable elements (TEs), which make up as much as two-thirds of the human genome 115 . For example, over 1.5 million degenerated long interspersed element (LINE) sequences are annotated in the human genome; although many are transcribed as parts of other genes, fewer than 100 of them are capable of retrotransposition 116 . This indicates that evolution constantly puts the degenerated TEs to new uses and, when present in transcribed regions, they are a rich source of new exons and other elements for post-transcriptional control 37, 117, 118 . The newly emerging Alu exons are controlled by an antagonistic interplay between two RBPs, HNRNPC and U2AF2, which compete for binding to U tracts, thus affecting the splicing outcome 8 (FIG. 1b) . Mutations that create a splice site can cause a major increase in the inclusion of an Alu exon, whereas mutations that change a single uridine within the U tract probably only slightly modify the inclusion of Alu exons. Thus, repression by HNRNPC might ensure that new Alu exons emerge gradually, rather than in discrete steps 119 . Notably, HNRNPC is a conserved protein in vertebrates, and therefore it has preceded the insertion of Alu elements into primate genomes. It remains unknown how such conserved RBPs controlled the transition of diverse classes of TEs within vertebrate genomes from a state of repressed TE-derived cryptic exons into functionally regulated alternative exons.
One way to explain the evolutionary functions of emerging non-canonical splicing events is the multilevel selection theory 120 . According to this theory, even if only a small number of individual species-or clade-specific TEs were beneficial at the level of organisms, the prevalence of TEs could have adaptive value for the species or clade by promoting speciation or preventing extinction. Similarly, the prevalence of cryptic splicing might increase the probability for the emergence of a few species-specific splicing events that can reset gene regulatory networks. Such evolutionary tinkering is particularly important for complex organisms, in which cryptic splicing appears to be linked to the increased size of the non-coding genomic regions 121 . Notably, the genes with the longest introns tend to be most highly expressed in the brain 14 , and these long introns produce the highest number of non-canonical splicing events 122, 123 . It remains to be seen whether and how such events may have contributed to the evolution of regulatory networks in vertebrate brains.
By decreasing the expression of new transcript variants produced by non-canonical splicing, cellular quality control pathways not only protect our cells from their potentially toxic effects, but they also decrease the negative selection against these variants during evolution. Thus, the low expression level of transcripts produced by non-canonical splicing provides an opportunity for evolution to test the newly emerging variants and to select against toxic protein isoforms before expressing them at higher levels. It remains to be seen if established transcripts that generate functional protein isoforms through alternative splicing in human cells might have initially emerged as cryptic splicing events in an ancestral species and were then gradually co-opted by evolution for new functions. All borders of human exons within Ensembl v83 multi-exon transcripts that overlap with Reference Sequence (RefSeq) database mRNA IDs were used. Identical coordinates from overlapping transcripts were collapsed into a single occurrence so that junctions were not counted multiple times. The first exons had only their exon-intron junction evaluated, whereas terminal exons had only their intron-exon junction evaluated. This led to a total of 189,255 5′ splice sites (left panels, with the black line marking the exon-intron border) and 187,091 3′ splice sites (right panels, with the black line marking the intron-exon border). Splice site sequences of U12-type introns were obtained from the U12 Intron Database 191 . After identifying the 5′ and 3′ sites that overlap with the respective U11-type and U12-type splice sites, the remaining U2-type intron splice site sequences were examined. 5′ and 3′ splice sites were classified independently and sequentially based on the indicated nucleotides. For example, 53.58% of unique U1-type exon-intron junctions contain GTRAG, and the remaining U1-type junctions were classified on the basis of the first two intronic nucleotides, GT. The percentage of unique junctions containing each motif is indicated. Weblogo 3 was used to show the relative frequency of nucleotides at each position 192 . a | Consensus motifs of the U1-type 5′ splice sites with GT at the border and the U2-type 3′ splice sites with AG at the border. b | Consensus motifs of the U11-type 5′ splice sites and U12-type 3′ splice sites. c | Consensus motifs of U1-type 5′ splice sites with GC at the border, or with TN or VN at the border (in which N stands for any nucleotide, and V stands for any nucleotide except T), and U2-type 3′ splice sites with BG or W at the border (in which B stands for any nucleotide except A, and W stands for T or A).
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Ataxia telangiectasia
An autosomal recessive disorder involving cerebellar degeneration, immunodeficiency, chromosomal instability, radiosensitivity and cancer predisposition. It is caused by mutations in ataxia telangiectasia mutated (ATM).
Laron syndrome
An autosomal recessive disorder characterized by short stature caused by mutations in growth hormone receptor (GHR).
Duchenne muscular dystrophy
A progressive proximal muscular dystrophy caused by mutations in dystrophin (DMD).
Hyperphenylalaninaemia
A neurologic disorder caused by autosomal recessive mutations in the genes encoding enzymes involved in the synthesis or regenerationof the BH4 (tetrahydrobiopterin) cofactor. The most common form is caused by mutations in PTS (6-pyruvoyl tetrahydropterin synthase).
Autophagy
Intracellular pathway responsible for regulated disassembly of unnecessary or dysfunctional cellular components after their targeting to lysosomes.
Non-canonical splicing and disease Disease-associated variations. Approximately onethird of disease-causing mutations are presently estimated to disrupt pre-mRNA splicing [124] [125] [126] . This effect can occur either by mutations in cis-elements within pre-mRNAs, or by mutations or misregulation of trans-regulatory factors that bind to pre-mRNAs 5 . This figure may be an underestimate, as it does not include the disease-linked synonymous variants within exons that can affect splicing 127 . Moreover, even though standard computational models focus on positions close to canonical splice sites to identify variants that might affect RNA splicing, new models are being developed that can predict variants at other positions 128 . These models were successful in the analysis of variants in spinal muscular atrophy (SMA), colorectal cancer and autism spectrum disorder (ASD).
Mutations that are located far from canonical splice sites can activate non-canonical splicing to cause disease 12, 86, [129] [130] [131] [132] [133] [134] [135] [136] [137] [138] [139] . For example, the core spliceosomal component U1 snRNP can repress cryptic exons when it binds in a non-productive conformation (FIG. 6a) . Deletion of the repressive U1 snRNP binding sites was found to activate splicing of cryptic exons in both ataxia telangiectasia and Laron syndrome 110, 140 . Generally, most studied mutations that induce splicing of cryptic exons achieve this by inactivating repressive sequences or secondary structures [133] [134] [135] or by increasing the strength of a cryptic splice site (FIG. 6b) . Moreover, disruption of canonical splicing can activate distal cryptic poly adenylation sites 136, 137 (FIG. 6b) . For example, triplet repeats within the first exon of the huntingtin (HTT) transcript inhibit splicing of the following intron, thereby activating a cryptic polyadenylation site within the intron 138 . The resulting transcript can be translated into short toxic peptides that contribute to the molecular pathogenesis of Huntington disease.
About half of the cryptic exons that are linked to disease are derived from TEs, particularly Alu elements, which have diverged from their original sequence by accumulating mutations that create splice sites 37, 141 . For example, a cryptic Alu-derived exon can disrupt the expression of dystrophin (DMD), thereby causing the Duchenne muscular dystrophy phenotype 130 . A particularly rich source of variation within the antisense Alu elements are the U tracts, which can control the formation of an Alu exon by affecting the competition between HNRNPC and U2AF2 (REFS 8, 129) . This mechanism has been seen in PTS (6-pyruvoyltetrahydropterin synthase), in which a >50 nt deletion containing the U tract leads to splicing of a cryptic Alu exon (FIGS 3b,6b), which disrupts PTS expression and leads to the neurological condition hyperphenylalaninaemia 129 . In addition to cis-acting mutations, a change in the activity of a trans-acting factor can perturb noncanonical splicing in a manner that leads to disease 12, [142] [143] [144] [145] [146] . A link between the reduced expression of SRRM4 mRNA and the decreased splicing of microexons was also observed in individuals with ASD 12 (FIG. 1c) . Moreover, TDP43, a major component of protein aggregates in ~50% of cases of frontotemporal dementia and in ~98% of amyotrophic lateral sclerosis cases, was found to repress splicing of a large number of cryptic exons with potential relevance for disease mechanisms 9 . The resulting disease-associated inclusion of a cryptic exon into the autophagy-associated gene, ATG4B (autophagy-related 4B cysteine peptidase), might lead to the defects in autophagy that are commonly linked to these diseases 147 . In addition, mutations in components of the minor spliceosome can lead to specific diseases by causing retention of U12-type introns, without affecting U2-type introns [142] [143] [144] [145] [146] 148 . The disease associations of other recently described non-canonical splicing events remain to be examined. Although potential roles of circRNAs in disease have been suggested 139, 149, 150 , they might also be candidates for disease biomarkers owing to their high levels of stability 151, 152 . Genes that undergo recursive splicing have been linked to neurodevelopmental disorders 14 , but it remains to be seen whether variations in RS sites are involved in these diseases.
Non-canonical splicing in cancer.
A prevalent feature of most cancer types is widespread intron retention 131, [153] [154] [155] . This could be associated with competition for the spliceosome owing to the high transcriptional activity in tumours, as limiting spliceosomal activity is a known cause of intron retention 156 (FIG. 6c) . Intron retention more often occurs in genes encoding RNA splicing and export factors, and therefore it may perturb the autoregulatory mechanisms of these genes in cancers. Moreover, enrichment in intron retention is associated with the presence of somatic single-nucleotide variants in cancer, particularly in tumour-suppressor genes 154 . Cancer-associated mutations in splicing factors such as U2AF1 or splicing factor 3b subunit 1 (SF3B1) can also promote intron retention or use of alternative 3′ splice sites 94, 157 . It was proposed that mutations in SF3B1 induce the selection of cryptic 3′ splice sites through the use of a different branch point 94, 95 , which leads to partial inclusion of the 3′ end of the intron. Importantly, half of these aberrantly spliced transcripts are NMD-sensitive and lead to downregulation of corresponding mRNAs and proteins 94 . Finally, differential splicing of several exitrons has been observed in breast cancer 26, 158 . Genomic deletion breakpoints and chromosomal rearrangements that generate chimeric transcripts are another common feature of cancer. Notably, the same chimeric transcripts can also be detected at a lower level in non-cancer cells that do not contain the chromo somal rearrangement. In this case, trans-splicing generates the chimeric transcript. For example, the JAZF1-SUZ12 (also known as JAZF1-JJAZ1) and the PAX3-FOXO1 chimeric transcripts are normally generated by trans-splicing of independent transcripts in both endometrial and mesenchymal stem cells, whereas chromosomal rearrangements result in the fusion of these genes in endometrial stromal tumours and rhabdomyosarcomas, respectively 86, 132 (FIG. 4d) . This could suggest that parental genes have properties, such as spatial gene proximity or sequence features, that facilitate the trans-splicing of individual transcripts in wild-type cells and chromosomal rearrange ments through homolo gous recombination in cancer cells. Alternatively, constitutive generation of trans-spliced molecules in wild-type cells might in some way facilitate the long-term chromosomal rearrange ments observed in cancer by unknown mechan isms. Furthermore, cis-splicing between adjacent genes also commonly produces chimeric transcripts in Figure 6 | Cryptic splicing in disease and therapeutic strategies. a | Cryptic exons are normally repressed by RNA-binding proteins (RBPs) such as heterogeneous nuclear ribonucleoprotein C (HNRNPC) or by U1 small nuclear ribonucleoproteins (snRNP). b | Examples of mutations (α, β, γ and δ) in deep intronic regions that can activate cryptic splicing events in disease-associated genes. Mutation α: HNRNPC binding to a poly(U) tract (U tract) upstream of an antisense Alu element represses recognition of the cryptic 3′ splice site within the element. Intronic deletions or point mutations that shorten the U tract can impede HNRNPC recruitment but allow U2 small nuclear RNA auxiliary factor (U2AF2) binding, leading to Alu exonization. A deletion within an Alu in the PTS gene (encoding 6-pyruvoyltetrahydropterin synthase) leads to splicing of an Alu exon that introduces a frameshift, thereby causing the neurologic disease hyperphenylalaninaemia 8, 141 . Mutation β: in ataxia telangiectasia mutated (ATM), U1 snRNP binding to an intronic element within a cryptic exon inhibits its recognition as a splicing competent exon. Patients with ataxia telangiectasia present a 4 nt deletion that abolishes U1 snRNP interaction, causing cryptic exon activation 110 . Mutation γ: a point mutation within a deep intronic sequence of cystic fibrosis transmembrane conductance regulator (CFTR) generates an active 5′ splice site that allows insertion of a cryptic exon within the CFTR transcripts, which causes cystic fibrosis 135 . Mutation δ: in breast cancer 2 (BRCA2), a point mutation that disrupts a canonical 3′ splice site activates an upstream cryptic exon (grey arrow) 136 . Disrupted BRCA2 expression causes breast, ovarian and other cancer types. c | New therapeutic strategies in cancer involve spliceosome targeting 156, 161, 162 . In MYC-driven tumours, oncogenic MYC causes transcriptional amplification, which overloads the splicing machinery and makes these cells more sensitive to alterations in splicing fidelity. Genetic knockdown or pharmacological inhibition of spliceosomal components leads to the accumulation of retained introns, which results in increased apoptosis and reduced tumorigenic and metastatic potential of MYC-driven tumours. Nature Reviews | Genetics 
A genetic blood disorder characterized by a defective synthesis of the β-globin chains of haemoglobin, thus causing abnormal erythropoiesis and anaemia.
Aptamers
Oligonucleotide (or peptide) molecules that have secondary and tertiary structures that strongly bind to specific proteins or other cellular targets.
Co-transcriptional decay
RNA surveillance mechanism that acts in the nucleus while transcripts are still associated with the chromatin template.
cancer, such as the SLC45A3−ELK4 fusion transcript in prostate cancer 159, 160 . Taken together, these observations suggest that non-canonical splicing events such as intron retention and chimeric transcripts could have important roles in cancer.
Therapeutic opportunities. Splicing can be exploited for three types of therapeutic strategies: those that modify the activity of splicing factors, those that change specific splicing events and those that exploit noncanonical splicing mechanisms. The first holds particularly great potential in certain types of cancer in which genetic knockdown or pharmacological inhibition of spliceosomal components can prevent the growth and metastasis of MYC-driven tumours 156, 161, 162 . In spite of these components being required in all cells, the increased demand for spliceosomal components induces accumulation of retained introns and increases apoptosis, specifically in tumours (FIG. 6c) .
In cases in which specific splicing events need to be corrected, pioneering studies restored normal splicing of β-globin in β-thalassaemia through the use of chemically modified antisense oligonucleotides (ASOs) that sterically block binding of the splicing machinery and avoid RNase H-mediated degradation of the target RNA 163 . This approach was successful in correcting the aberrant splicing in SMA and many other diseases 164, 165 . Antisense sequences can also be delivered as modified U snRNA molecules, using viral vectors that efficiently transfer a modified U snRNA gene into the affected tissue, which allows continuous expression without the need of repetitive administration 166, 167 . Both ASOs and modified U snRNAs can be directed to splice sites, branch points or other regulatory elements, such as splicing enhancers or silencers, and therefore were successfully used to prevent the splicing of cryptic exons in a variety of diseases that are caused by deep-intronic mutations 155, [165] [166] [167] [168] [169] . To increase their efficiency, bifunctional ASOs or U snRNAs can be designed to contain an RNA-binding domain and an effector domain, which recruits splicing factors that either enhance or silence splicing 170, 171 . Finally, therapeutic strategies based on CRISPR-Cas9 genome editing have recently been successful to induce exon skipping in vivo in adult mice [172] [173] [174] , indicating that this tool may prove valuable as a therapy to correct various types of canonical and cryptic splicing events in human diseases.
Several non-canonical splicing mechanisms can also be exploited as therapies. Trans-splicing has been applied to correct genetic mutations in monogenic disorders. In this technique, known as spliceosomemediated RNA trans-splicing (SMaRT), specific regions within the mutated mRNA are replaced using engineered RNA trans-splicing molecules as templates 175, 176 . These template molecules contain the wild-type mRNA sequence to be replaced, a domain with the essential splicing elements and a domain that binds the target region. This strategy has been applied to many diseases, such as muscular dystrophies, haemophilia and cancer 176, 177 . Other types of non-canonical events might also prove useful for therapies; for example, the designed artificial circRNAs that could serve as aptamers, trans-cleaving ribozymes, small interfering RNAS (siRNAs), or as sponges to sequester mi RNAs or RBPs 151, 178 .
Future perspectives
In this Review we have seen how new methods have led to the discovery of various types of splicing events. The next challenge will be to systematically examine non-canonical splicing events that occur as a result of genetic variation, as this would clarify their importance from the perspective of evolution and disease. So far, many of the mutations affecting splicing have been identified by exome sequencing, which can only identify intronic mutations within a limited region around the annotated exon-intron boundaries. Therefore, genome-wide sequencing will be required to reveal the full range of intronic variation that can activate cryptic splicing, perturb distal branch points or disturb regulatory regions 32 . It is also important to bear in mind that abnormally processed pre-mRNAs can interfere with transcription or cause co-transcriptional decay 36, 179 . Dedicated genomic and transcriptomic experiments and computational approaches are needed to detect the full range of mutations that cause disease through non-canonical splicing.
Even though it is clear that many non-canonical splicing events take place in human transcripts, our understanding of their roles in disease and physiology remains limited. We need a better understanding of their roles in generating alternative transcripts with modified stability, translation or localization, producing new protein isoforms, or sequestering specific RBPs and mi RNAs. We also need to uncover their roles in diversifying tissue-specific or cell-specific patterns of gene expression across populations 180, 181 . Many non-canonical splicing events are enriched in the central nervous system, including cryptic exons 10 , microexons 12 , RS sites 14, 15 and circRNAs 182 . Much remains to be discovered about how these mechanisms contribute to the complexity of gene regulation and the diversity of protein isoforms produced in the brain.
As the next round of ENCODE (Encylopedia of DNA Elements) data on protein-RNA interactions becomes available, an understanding of non-canonical splicing events that are hidden deep within introns will be crucial to explaining those interactions for which a function has not yet been identified 183 . Chromatin structure, DNA methylation, histone marks, nucleo some positioning and the kinetics of transcriptional elongation all contribute to splicing regulation in coordination with RBPs and the spliceosome 184 . It remains to be seen if these factors cooperate in the control of non-canonical splicing. It is likely that diverse regulatory inter actions within intronic regions contribute to the quality control mechanism that prevents aberrant cryptic spli cing from causing disease 27 . Nevertheless, it is clear that many non-canonical splicing events escape this quality control, and their role as a source for new molecular functions during evolution will remain a fascinating subject of research for many years.
